June 5, 2010Open Access

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Key Points

Key points are not available for this paper at this time.

Abstract

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Hodi et al. (Sat,) studied this question.

www.synapsesocial.com/papers/6991393dd1ef3d049e6cff6c — DOI: https://doi.org/10.1056/nejmoa1003466

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Toxicity and response criteria of the Eastern Cooperative Oncology Group· 1982 · 11,558 citations
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4· 2005 · 1,011 citations
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma· 2004 · 569 citations
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review

Authors

F. Stephen Hodi

Steven O’Day

David F. McDermott

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

Washington University in St. Louis

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion